KRAS and non-small cell lung carcinoma: Currently, the phase III KRYSTAL-12 trial (NCT04685135) will assess the efficacy of adagrasib versus docetaxel in patients with advanced NSCLC and KRAS G12C mutation who have progressed during or after treatment with a platinum-based regimen and an immune checkpoint inhibitor [68].